Study of OCV-501 in Patients With Acute Myeloid Leukemia (AML) [EXTENSION OF 700207140]
Latest Information Update: 07 Dec 2021
Price :
$35 *
At a glance
- Drugs OCV 501 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Otsuka Pharmaceutical
- 22 Dec 2017 Status changed from active, no longer recruiting to completed.
- 20 Mar 2014 New trial record